Two head-to-head trials comparing the safety of Incruse Ellipta to 2 available bronchodilator treatments used by patients with chronic obstructive pulmonary disease has yielded positive results for GlaxoSmithKline's therapy.
Two head-to-head trials comparing the safety of Incruse Ellipta (umeclidinium) to 2 available bronchodilator treatments used by patients with chronic obstructive pulmonary disease (COPD) has yielded positive results for GlaxoSmithKline’s therapy.
In 12-week multi-center, randomized, blinded study of 1259 patients, the once-daily 62.5 mcg dose of umeclidinium achieved a statistically significant improvement in lung function as 12 weeks compared to a once-daily 18 mcg dose of tiotropium.
The second study was a 12-week multi-center, non-US, randomized, open-label study, which found that the once-daily 62.5 mcg dose of umeclidinium was non-inferior to a once-daily 44 mcg dose of glycopyrronium.
The most common side effects for all 3 treatments were headache and nasopharyngitis.
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More